Stock CYTORI THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cytori Therapeutics Inc Deutsche Boerse AG

Equities

US23283K1051

End-of-day quote Deutsche Boerse AG
Other stock markets
- EUR - Intraday chart for Cytori Therapeutics Inc
Jun. 07 Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024 CI
Jun. 07 Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
AQ
Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update for Initial Safety, Feasibility and Preliminary Efficacy
PU
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024
CI
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program
MT
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
AQ
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc
CI
Plus Therapeutics Announces New Employment Inducement Grants
AQ
Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
Plus: Q1 Earnings Snapshot
AQ
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
AQ
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
AQ
Plus Therapeutics : Material Agreement - Form 8-K
PU
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
AQ
Transcript : Plus Therapeutics, Inc. - Special Call
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.
CI
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC
CI
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
AQ
Plus Therapeutics : The use of CNSide in Clinical Management of LMD
PU
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTV Stock
  4. Stock
  5. News Cytori Therapeutics Inc